Table 1.
Summary of efficacy data from randomized, controlled phase III trials of bevacizumab in advanced ovarian cancer
| Study | Regimen | ORR (CR + PR), % | Median PFS, mon | Median OS, mon |
|---|---|---|---|---|
| GOG-0218 [21] (n = 1,873) | CP + placebo vs. CP + Bev vs. CP + Bev→Bev maintenance | - | 10.3 vs. 11.2 vs. 14.1 | 39.3 vs. 38.7 vs. 39.7 |
| (HR, 0.908; p = 0.16)a | (HR, 1.036; p = 0.76)a | |||
| (HR, 0.717; p < 0.001)b | (HR, 0.915; p = 0.45)b | |||
| ICON 7 [22,23] (n = 1,528) | CP vs. CP + Bev→Bev maintenance | 48 vs. 67 | 17.4 vs. 19.8 | 44.6 vs. 44.5 |
| (p < 0.001) | (HR, 0.87; p = 0.04) | |||
| OCEANS [24,27] (n = 484) | CG + placebo vs. CG + Bev | 57.4 vs. 78.5 | 8.4 vs. 12.4 | 33.6c vs. 32.9c |
| (p < 0.0001) | (HR, 0.484; p < 0.0001) | (HR, 0.960; p = 0.736) | ||
| AURELIA [28,29] (n = 361) | CTx (PLD, P, or Top) vs. CTx + Bev | 11.8 vs. 27.3 | 3.4 vs. 6.7 | 13.3 vs. 16.6 |
| (p = 0.001) | (HR, 0.48; p < 0.001) | (HR, 0.85; p = 0.174) |
ORR, overall response rate; CR, complete response; PR, partial response; PFS, progression-free survival; OS, overall survival; GOG, Gynecologic Oncology Group; C, carboplatin; P, paclitaxel; Bev, bevacizumab; HR, hazard ratio; ICON, International Collaborative Ovarian Neoplasm; OCEANS, platinum-sensitive recurrent disease; G, gemcitabine; AURELIA, platinum-resistant ovarian cancer; CTx, chemotherapy; PLD, pegylated liposomal doxorubicin; Top, topotecan.
a
CP + Bev vs. CP + placebo.
b
CP + Bev→Bev vs. CP + placebo.
c
Interim data.